Sizodon-LS

Quick links to important sections

Sizodon-LS

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sizodon-LS

Quick Facts

Property Description
Active ingredient Risperidone and Trihexyphenidyl Hydrochloride
Form Tablet
Pharmacological class Atypical Antipsychotic, Anticholinergic
General Purpose Stabilizing thought processes and mitigating movement issues
Origin Synthetic

What Type of Medicine is Sizodon-LS?

Sizodon-LS is defined as a synthetic, prescription-only fixed-dose combination medication that belongs to two key pharmacological classes: the Atypical Antipsychotic group and the Anticholinergic agent group. This specific combination is clinically recognized for its targeted management approach to certain severe psychiatric conditions. The structural nature of Sizodon-LS is a unified product, distinguishing it from treatments where the components are taken separately.

Composition: The Dual Active Ingredients and Form

The medication is supplied for the oral route as a tablet and contains two primary active ingredients by their International Non-proprietary Names (INN): Risperidone and Trihexyphenidyl Hydrochloride. Risperidone is the core antipsychotic component, which is a second-generation antipsychotic known for its complex action on dopamine and serotonin pathways. Trihexyphenidyl Hydrochloride serves as the synthetic anticholinergic agent, widely employed to manage movement-related side effects associated with antipsychotic treatment. As a fixed-dose combination, the drug contains both chemical entities integrated into the solid excipient base of the tablet dosage form.

What is the General Purpose of Combining These Two Agents?

The general purpose of combining these two agents is to facilitate a comprehensive approach by coupling mental stabilization with physical support. The formulation uses the Risperidone component to modulate brain chemistry, while the Trihexyphenidyl Hydrochloride component is included to mitigate the risk of specific movement disturbances, such as involuntary stiffness and tremors (extrapyramidal symptoms). This integrated strategy promotes mental stability while supporting controlled movement and overall patient comfort. For example, the medication is typically used to support individuals undergoing treatment for psychotic disorders who experience motor side effects.

Regulatory References

  1. National Institutes of Health (NIH)
  2. MedlinePlus

What side effects are possible with Sizodon-LS?

Possible Side Effects and Safety Information

This section outlines the possible adverse reactions and safety characteristics of Sizodon-LS (containing Risperidone and Trihexyphenidyl Hydrochloride) as classified in official regulatory documentation. The safety profile incorporates effects from both the antipsychotic and anticholinergic components.


Frequency and System-Organ Classifications

Classification Common Examples Affected System Organ Classes
Very Common (ge 10%) Parkinsonism, Headache, Sedation Nervous System Disorders
Common (ge 1% to < 10%) Akathisia, Dizziness, Increased Weight Nervous System, Metabolism & Nutrition, Gastrointestinal
Anticholinergic Effects (30–50%) Dry Mouth, Blurred Vision, Constipation Gastrointestinal, Eye Disorders, Nervous System

The anticholinergic effects of Trihexyphenidyl, such as dry mouth and blurred vision, are often documented as becoming less pronounced as treatment continues. Effects like orthostatic hypotension (a drop in blood pressure upon standing) are noted to occur especially during the initial phase of dose adjustment.


Documented Serious Adverse Reactions and Safety Notes

Official labeling describes rare but potentially serious events associated with the antipsychotic component, including Neuroleptic Malignant Syndrome (NMS), a severe, rare condition, and Tardive Dyskinesia (TD), a syndrome of involuntary movements that may develop with long-term use. Other serious safety concerns include significant Metabolic Changes (e.g., hyperglycemia, weight gain) and Cerebrovascular Adverse Reactions.

Safety notes also exist for specific patient groups: Antipsychotic use is associated with an increased risk of death in older adults with dementia-related psychosis, and this medication is not approved for that condition. Patients with severe renal or hepatic impairment may require particular caution due to potential changes in drug clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Sizodon-LS, containing Risperidone and Trihexyphenidyl, reflects the combined risks of an atypical antipsychotic and an anticholinergic agent, and requires immediate medical attention upon suspected ingestion of an excessive dose.

Overdose may present with serious manifestations documented in regulatory sources, including signs of Central Nervous System (CNS) depression such as drowsiness and sedation, potentially progressing to seizures or coma.

Cardiovascular risks are officially documented and include tachycardia (fast heart rate), hypotension (low blood pressure), and the potential for severe ventricular arrhythmias like Torsades de Pointes. Manifestations of anticholinergic toxicity, such as mydriasis, urinary retention, and hyperthermia, are also noted in official labeling.

Regulatory authorities mandate that any suspected overdose requires prompt evaluation by a physician and that Poison Control Centers be contacted immediately. Management is described as symptomatic and supportive, aiming to establish and maintain a clear airway and ensure adequate oxygenation.

Official documents specify that continuous ECG monitoring and close medical supervision are required until full recovery. It is also officially noted that no specific antidote is known for the Risperidone component. Patients with hepatic or renal impairment may be more susceptible to increased overdose severity, as stated in regulatory materials.

Therapeutic Uses of Sizodon-LS

What Sizodon-LS Treats: Main Uses and Benefits

Sizodon-LS is commonly used across conditions characterized by periods of heightened symptoms, providing supportive relief that helps patients cope more steadily with difficult episodes. It plays a role in managing key symptom domains and may assist with maintaining functional stability.


Managing Severe Psychotic and Affective Manifestations

This combination medication is primarily applied in contexts requiring additional symptomatic support in major psychotic disorders and conditions marked by profound emotional tension, such as Schizophrenia and acute manic or mixed episodes of Bipolar I Disorder. The active ingredient, Risperidone, is commonly used for the symptomatic management of these conditions and the accompanying manifestations like hallucinations, delusions, and severely disorganized thinking. It helps address symptom clusters that may become intense or disruptive. This provides support that helps ease the overall symptom burden.

Easing Drug-Induced Motor Discomfort

A relevant application of this combination is applied in addressing involuntary motor disturbances, or extrapyramidal symptoms (EPS), that may arise during antipsychotic treatment. It is relevant when physical symptoms, such as debilitating tremors, muscle stiffness, or severe restlessness (akathisia), create noticeable interference with daily stability. The supportive therapeutic benefit provided by the second agent, Trihexyphenidyl, may contribute to easing physical discomfort, which assists with maintaining functional stability.


“The combination formulation is used when symptomatic relief is needed across both mental and motor domains.”


Therapeutic Focus: Management of Dual Symptoms

This combination is commonly used to help manage symptoms across two domains: symptoms related to systemic imbalance (psychotic and affective symptoms) and involuntary motor disturbances (drug-induced EPS).

Eligibility and Restrictions for Use

Who can and cannot use Sizodon-LS?

The eligibility for the fixed-dose combination Sizodon-LS (Risperidone and Trihexyphenidyl HCl) is strictly defined by regulatory guidance, focusing on age and pre-existing medical conditions.


Population/Condition Official Regulatory Status
Absolute Contraindications Hypersensitivity to any component; Narrow-angle glaucoma; Gastrointestinal or Urinary Tract Obstruction (due to anticholinergic effects).
Age-Related Restrictions Not recommended for children and adolescents under 18 years as safety and efficacy data for the combination are not established.
Elderly patients with dementia-related psychosis are not recommended to use the Risperidone component due to elevated risks.
Conditional Use Required Patients with severe renal or hepatic impairment should use with caution and may require a lower initial dose.
Physiological State Breastfeeding is generally not recommended or contraindicated. Use during pregnancy is avoided unless necessary, with warnings for newborns exposed in the third trimester.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Sizodon-LS (Risperidone and Trihexyphenidyl) primarily through alterations in drug exposure and additive effects on the central nervous system (CNS).


Pharmacokinetic Interactions

Co-administration with strong inhibitors of the CYP2D6 enzyme (e.g., Fluoxetine, Paroxetine) or P-glycoprotein (P-gp) transporters (e.g., Itraconazole) increases the plasma concentration of the Risperidone active fraction. Conversely, inducers of CYP3A4 and P-gp (e.g., Carbamazepine, Rifampicin) or the herbal product St John's wort decrease the drug's exposure. These changes in plasma levels may necessitate a re-evaluation of the treatment plan upon initiation or discontinuation of the interacting agent.


Pharmacodynamic Interactions and Restrictions

The dual components have documented additive CNS depressant effects, which is the basis for the restriction that alcohol must be avoided. The co-administration of other centrally-acting medicines may also enhance sedation. Caution is advised with antihypertensive agents due to the potential for enhanced hypotensive effects. Due to the anticholinergic activity of Trihexyphenidyl, co-administration with highly irritating potassium salts is not recommended due to the risk of gastrointestinal complications. Additionally, caution is noted with medicines known to prolong the QT interval.


Population-Specific Interaction Note

In patients with renal or hepatic impairment, the drug's reduced elimination capacity amplifies the effects of co-administered metabolic inhibitors and inducers.

Mechanism of Action

The mechanism of Sizodon-LS is based on the complementary pharmacological actions of its two active ingredients, modulating central neural signaling and countering mechanism-induced motor dysregulation.

Modulating Serotonin and Dopamine Receptor Activity

The primary component, risperidone, acts as an antagonist (blocker) primarily at Serotonin mathbf5- HT2 A receptors and Dopamine mathbf D2 receptors in the Central Nervous System. This simultaneous antagonism modifies activity across the mesolimbic and mesocortical dopaminergic pathways. The dual action reduces excessive signaling in certain circuits and alters dopamine outflow in key brain regions, influencing perceptual and cognitive function.


Correcting the Motor Control Pathway Imbalance

The secondary component, trihexyphenidyl, provides a corrective mechanism. It acts as an anticholinergic agent by competitively blocking muscarinic acetylcholine receptors in the nigrostriatal motor pathway. This action counteracts a functional state where D2 receptor blockade causes an over-dominance of acetylcholine activity in the motor circuit. By blocking muscarinic receptors, trihexyphenidyl restores the necessary neurochemical equilibrium between dopamine and acetylcholine. This corrective modulation influences muscle tone and movement execution.

Dosage and Administration Information

How to Use Sizodon-LS

This section describes the official administration principles for the fixed-dose combination product containing Risperidone and Trihexyphenidyl Hydrochloride, based strictly on regulatory documents. It does not provide medical advice.


Administration and Dosage Principles

Feature Official Usage Principle
Route of Administration The medication is approved for the oral route only, administered as a tablet.
Titration and Dosing Treatment starts with a low initial dose of the Risperidone component and is gradually titrated (increased) over several days to reach an individualized maintenance dose. The maintenance dose range for Risperidone in adults is typically 4 to 8 mg daily, with a specified maximum dose.
Frequency The total daily dosage is generally administered once daily or in divided doses twice a day.
Timing with Meals The tablet may be taken with or without food, providing flexibility in the daily schedule.

Population and Procedural Rules

Official instructions mandate specific procedural steps for safe and effective use. The tablet must be swallowed whole with water and should not be crushed, chewed, or broken.

Population-specific adjustments are required for certain groups. Older adults typically require a reduced initial dose (e.g., 0.5 mg of the Risperidone component twice daily) and a slower rate of dose increase due to heightened sensitivity. Similarly, patients with severe renal or hepatic impairment are instructed to begin with a lower starting dose and use a conservative titration schedule. The official protocol also requires that the medication be discontinued gradually via a tapering regimen, as abrupt cessation may lead to the return of symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies

The Sizodon-LS combination contains Risperidone (an atypical antipsychotic) and Trihexyphenidyl (an anticholinergic agent). Research concerning this combination is primarily focused on the management of psychiatric conditions and the mitigation of associated motor effects.

Evaluating Efficacy in Schizophrenia and Psychosis

Studies investigated the use of Risperidone in patients with schizophrenia and related psychotic disorders. This research explored how the compound was investigated in patients with these conditions.

  • Role of Combination Therapy: Trihexyphenidyl is included in the combination, as research has examined its effect on the extrapyramidal symptoms (EPS), such as involuntary muscle movements, that may be experienced by patients taking antipsychotic medications like Risperidone.
  • Secondary Outcomes: Research has evaluated whether the combination affected overall functional measures and quality of life indicators for individuals receiving treatment.

Long-Term Administration and Safety Profile

Clinical trials have examined the sustained use of Risperidone-containing regimens over extended periods to evaluate long-term response and tolerability.

  • Safety in the Elderly: Studies have examined the long-term administration in the elderly population to assess reported side effects. The study’s findings indicated that the side effect profile in this demographic may be monitored carefully due to age-related sensitivities.
  • Impact on Sleep: Trials have reported on the effect on patient-reported sleep quality, noting changes in sleep duration and incidence of drowsiness among participants.

Reported Adverse Events and Exclusions

The most frequently reported adverse events in clinical settings have included dizziness, sedation, dry mouth, and blurred vision, which are common to the components.

  • Cardiovascular Events: The trial protocols included specific monitoring parameters for changes in heart rate and blood pressure. Hypertension has been reported as an adverse event in a subset of participants.
  • Drug Interactions: Studies examined the interaction of the combination drug with other commonly prescribed psychiatric and non-psychiatric medications. The researchers reported an increased risk of certain adverse effects when taken concurrently with central nervous system depressants or specific QTc-prolonging agents.

Frequently Asked Questions (FAQ)

Common questions about Sizodon-LS (FAQ)

Q: Is Sizodon-LS a sleeping pill or an anti-anxiety medicine?

A: Sizodon-LS is officially classified as an atypical antipsychotic combined with an anticholinergic agent. Its main purpose, as described in official product information, is to help stabilize thought processes and mitigate movement issues that may be related to certain severe psychiatric conditions. It is not classified as a dedicated sleeping pill or an anti-anxiety medicine.

Q: Why is Sizodon-LS sometimes called a mood stabilizer?

A: Although the drug is primarily an antipsychotic, its main active component (risperidone) has regulatory indications for use in the treatment of Bipolar I Disorder. Since medications used to manage this disorder are commonly referred to as 'mood stabilizers' in a general clinical context, the term may be used when discussing the drug's use for bipolar symptoms.

Q: Is it normal to feel a bit restless when first starting Sizodon-LS?

A: Restlessness (akathisia) is a commonly reported side effect, occurring in 1% to 10% of participants in clinical trials, according to product labeling. This experience is a recognized adverse event associated with the antipsychotic component.

Q: What is the difference between Sizodon-LS and other risperidone-containing medicines?

A: Sizodon-LS is a fixed-dose combination product. Unlike single-ingredient risperidone medicines, it contains two active ingredients: risperidone (the antipsychotic) and trihexyphenidyl hydrochloride (the anticholinergic agent) integrated into one tablet. This combination is formulated to pair mental stabilization with support for movement control.

Q: Can Sizodon-LS be used for children or teenagers?

A: Official regulatory guidance states that the fixed-dose combination product is not recommended for children and adolescents under 18 years of age. This restriction is in place because formal data on the safety and efficacy of this specific two-drug combination have not been fully established for that age group.

Q: How long can a person safely take Sizodon-LS?

A: Studies have examined the sustained use of risperidone-containing regimens over extended periods, indicating it is generally intended for long-term therapy for chronic conditions. Regulatory guidance emphasizes that the medication is generally subject to regular monitoring to evaluate long-term response and manage potential effects, such as involuntary movements.

Q: Can Sizodon-LS cause problems with memory or concentration?

A: Yes, regulatory information indicates that the anticholinergic component (trihexyphenidyl) can be associated with side effects such as confusion. Additionally, due to its effects on the central nervous system, the medication may influence cognitive functions like memory and concentration.

Q: Does Sizodon-LS have any known effects on fertility?

A: Official labeling notes that the antipsychotic component (risperidone) can elevate a hormone known as prolactin. Elevated prolactin levels may potentially lead to menstrual cycle changes and other hormonal imbalances that can affect fertility.

Q: Are there any specific times of day Sizodon-LS should be taken?

A: Official instructions state that the total daily dosage can generally be administered once a day or in divided doses twice a day. The tablet may be taken with or without food. Regulatory information indicates that because sedation is a very common side effect, the timing of administration is generally determined to help mitigate drowsiness.

Q: Is Sizodon-LS used to help with aggressive behaviors?

A: The active antipsychotic component (risperidone) is approved for the treatment of irritability symptoms in patients with autistic disorder. These irritability symptoms often include aggression and temper tantrums, suggesting a use case in managing these behaviors under medical guidance.

Q: How is the benefit of Sizodon-LS generally assessed by healthcare professionals?

A: The effectiveness of the medication is generally assessed by monitoring clinical response and looking at overall functional measures and quality of life indicators. Additionally, regulatory guidance recommends regular monitoring of potential side effects, including metabolic changes (like blood glucose) and involuntary movement disorders.

Q: What if I feel dizzy after taking Sizodon-LS?

A: Dizziness is a common side effect, as reported in regulatory documents. A drop in blood pressure upon standing (orthostatic hypotension) is also noted, particularly during the initial phase of dose adjustment. This is a recognized risk within the medication's safety profile.

Q: Is Sizodon-LS meant for short-term use only?

A: No, official research has examined the sustained use of risperidone-containing regimens over extended periods. This indicates the drug is generally utilized as a chronic or long-term therapeutic option for the conditions it addresses.

Q: Can Sizodon-LS be taken on an empty stomach?

A: Yes, official administration guidelines state that the tablet may be taken with or without food.

Q: Can Sizodon-LS affect my blood sugar levels?

A: Yes, official labeling notes that the drug is associated with a risk of significant Metabolic Changes, including hyperglycemia (high blood sugar). The potential for this change is the basis for regulatory guidance that includes the periodic monitoring of blood glucose levels.

Q: Does Sizodon-LS cause changes in appetite?

A: While regulatory documents do not directly name 'appetite change' as a side effect, they do list Increased Weight as a commonly reported event. Weight gain is an outcome that is often associated with an increase in appetite.

Q: What is the experience like for patients starting Sizodon-LS?

A: The initial experience involves a low starting dose that is gradually increased over time. During this initial adjustment, patients commonly report temporary side effects such as dizziness, sedation, and dry mouth. The process involves close monitoring as part of the standard treatment protocol.

Q: Is it important to check the ingredients of other medicines for interactions with Sizodon-LS?

A: The drug is known to have a complex interaction profile, which necessitates reviewing co-administered agents. It may interact with medicines that affect certain liver enzymes or with other drugs that cause central nervous system depression. Regulatory documents emphasize caution with specific agents that share these properties.

Q: How quickly do the effects of Sizodon-LS usually start?

A: Because the drug has two active components, the onset of effect varies. The anticholinergic component (trihexyphenidyl) may start to influence movement-related side effects within a few hours. However, the full beneficial effect of the antipsychotic component (risperidone) may take several weeks to be fully realized.

Q: Can Sizodon-LS affect my ability to drive or operate machinery?

A: Official safety precautions warn against operating heavy machinery, including driving, until a person knows how the medication affects them. This warning is due to common side effects like drowsiness, dizziness, and reduced concentration capacity.

Q: Are there known interactions between Sizodon-LS and herbal supplements?

A: The herbal product St John's wort is specifically noted in regulatory information as potentially decreasing the blood concentration of the drug’s active component. Regulatory guidance requires disclosure of all concurrent herbal and vitamin use to the prescribing professional.

Q: Is it necessary to have blood tests while on Sizodon-LS?

A: Periodic blood monitoring may be recommended by regulatory guidance. This monitoring is intended to assess for Metabolic Changes by reviewing parameters like fasting blood glucose and lipid profile before treatment initiation and periodically thereafter.

Q: Can Sizodon-LS be taken with multivitamins?

A: Specific interactions with multivitamins are not detailed in official regulatory documents. However, regulatory information indicates that it is important to disclose all concurrent medications and supplements, including vitamins and herbal products, to the prescribing professional due to potential interactions.

Q: What should a patient know about stopping Sizodon-LS?

A: The official protocol requires that the medication be discontinued gradually via a tapering regimen. It is important to know that abrupt cessation is associated with a possible return or worsening of symptoms that the medication was treating.

Q: Can Sizodon-LS cause changes in sleeping patterns other than drowsiness?

A: Yes, clinical trials have reported on patient-reported sleep quality. Studies noted changes in sleep duration and the incidence of drowsiness among participants, indicating the potential for sleep patterns to be influenced beyond simple sedation.

Q: What is the importance of regular follow-ups while using Sizodon-LS?

A: Regular follow-up is necessary to allow for the re-evaluation of the treatment plan, especially if interacting medications are started or stopped. It is also essential for the careful monitoring of known side effects, such as movement disorders and metabolic changes.

How should Sizodon-LS be stored and disposed of?

How to Store and Dispose of Sizodon-LS?

This medication must be stored according to official regulatory specifications to maintain its stability and safety. Keep Sizodon-LS in its original container, tightly closed, and stored at controlled room temperature, which is generally 15 to 30 C (59 to 86 F). Protect the medication from excess heat and moisture; therefore, storage areas like a bathroom are unsuitable. It is a mandatory requirement to store this drug securely, out of the sight and reach of children, and to use safety caps. Orally disintegrating tablets must be used immediately upon opening the sealed package.

Disposal should be managed according to governmental guidelines. The preferred method for discarding unused or expired medication is to use a drug take-back program or mail-back envelope. If these options are unavailable, the medication may be mixed with an unappealing substance (such as dirt or coffee grounds) and placed in a sealed container before being thrown in the household trash, ensuring personal information is scratched off the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sizodon-LS found in:

A-Z Index: